TR199902923T2 - Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri. - Google Patents

Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri.

Info

Publication number
TR199902923T2
TR199902923T2 TR1999/02923T TR9902923T TR199902923T2 TR 199902923 T2 TR199902923 T2 TR 199902923T2 TR 1999/02923 T TR1999/02923 T TR 1999/02923T TR 9902923 T TR9902923 T TR 9902923T TR 199902923 T2 TR199902923 T2 TR 199902923T2
Authority
TR
Turkey
Prior art keywords
trevleri
cresi
olarak
almas
yumu
Prior art date
Application number
TR1999/02923T
Other languages
English (en)
Turkish (tr)
Inventor
William End David
J. Zelesko Michael
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of TR199902923T2 publication Critical patent/TR199902923T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR1999/02923T 1997-06-02 1998-05-25 Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri. TR199902923T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4737697P 1997-06-02 1997-06-02

Publications (1)

Publication Number Publication Date
TR199902923T2 true TR199902923T2 (xx) 2000-11-21

Family

ID=21948611

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02923T TR199902923T2 (xx) 1997-06-02 1998-05-25 Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri.

Country Status (22)

Country Link
US (4) US6365600B1 (US06734194-20040511-C00023.png)
EP (1) EP0988038B1 (US06734194-20040511-C00023.png)
JP (1) JP4209472B2 (US06734194-20040511-C00023.png)
KR (1) KR100517832B1 (US06734194-20040511-C00023.png)
CN (2) CN100525766C (US06734194-20040511-C00023.png)
AT (1) ATE222104T1 (US06734194-20040511-C00023.png)
AU (1) AU740603B2 (US06734194-20040511-C00023.png)
BR (1) BR9810423A (US06734194-20040511-C00023.png)
CA (1) CA2290992C (US06734194-20040511-C00023.png)
DE (1) DE69807222T2 (US06734194-20040511-C00023.png)
DK (1) DK0988038T3 (US06734194-20040511-C00023.png)
ES (1) ES2182327T3 (US06734194-20040511-C00023.png)
HK (2) HK1025046A1 (US06734194-20040511-C00023.png)
ID (1) ID24675A (US06734194-20040511-C00023.png)
IL (1) IL133212A (US06734194-20040511-C00023.png)
NO (1) NO318834B1 (US06734194-20040511-C00023.png)
NZ (1) NZ501401A (US06734194-20040511-C00023.png)
PT (1) PT988038E (US06734194-20040511-C00023.png)
RU (1) RU2209066C2 (US06734194-20040511-C00023.png)
TR (1) TR199902923T2 (US06734194-20040511-C00023.png)
WO (1) WO1998055124A1 (US06734194-20040511-C00023.png)
ZA (1) ZA984700B (US06734194-20040511-C00023.png)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199902923T2 (xx) 1997-06-02 2000-11-21 Janssen Pharmaceutica N.V. Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri.
US20020099438A1 (en) * 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
PL193296B1 (pl) * 1998-07-06 2007-01-31 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
US7967855B2 (en) 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
EP1107962B1 (en) * 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
SK286072B6 (sk) * 1998-12-23 2008-02-05 Janssen Pharmaceutica N. V. 1,2-anelované chinolínové deriváty, spôsob ich prípravy, medziprodukty, farmaceutický prostriedok aich použitie
ID29584A (id) 1999-02-11 2001-09-06 Pfizer Prod Inc Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker
DE60008206T2 (de) 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
DK1650203T3 (da) 2000-09-11 2008-06-02 Novartis Vaccines & Diagnostic Quinolinonderivater som tyrosinkinaseinhibitorer
FR2813791B1 (fr) * 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
WO2002024682A1 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
DE60135919D1 (de) 2000-09-25 2008-11-06 Janssen Pharmaceutica Nv Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
EP1322636A1 (en) 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives
US7153958B2 (en) 2000-11-21 2006-12-26 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
ATE319704T1 (de) 2000-12-27 2006-03-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
EP1408971A4 (en) 2001-06-21 2006-01-25 Ariad Pharma Inc NEW QUINOLINES AND THEIR USES
ES2323265T3 (es) 2001-12-19 2009-07-10 Janssen Pharmaceutica Nv Derivados de quinolina condensados en 1,8 sustituidos con triazoles unidos por el carbono como inhibidores de la farnesil-transferasa.
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7241777B2 (en) 2002-03-22 2007-07-10 Janssen Pharmaceutica N.V. Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
AU2003229688B2 (en) 2002-04-15 2009-07-30 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US8016881B2 (en) 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US6638301B1 (en) * 2002-10-02 2003-10-28 Scimed Life Systems, Inc. Medical device with radiopacity
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
US20050154451A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7211108B2 (en) * 2004-01-23 2007-05-01 Icon Medical Corp. Vascular grafts with amphiphilic block copolymer coatings
NZ547277A (en) * 2004-01-23 2009-08-28 Janssen Pharmaceutica Nv Substituted quinolines and their use as mycobacterial inhibitors
CN1960731B (zh) 2004-02-20 2011-12-07 诺华疫苗和诊断公司 调节炎性和转移过程的方法
US7332605B2 (en) * 2004-03-15 2008-02-19 Anormed, Inc. Process for the synthesis of CXCR4 antagonist
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital TREATMENT OF SYNUCLEINOPATHIES
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US7063720B2 (en) * 2004-09-14 2006-06-20 The Wallace Enterprises, Inc. Covered stent with controlled therapeutic agent diffusion
US20060083770A1 (en) * 2004-10-15 2006-04-20 Specialty Coating Systems, Inc. Medical devices and methods of preparation and use
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US20060200048A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Removable sheath for device protection
WO2006110197A2 (en) 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
SG154451A1 (en) 2005-05-23 2009-08-28 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
NZ566180A (en) 2005-07-29 2011-04-29 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
US20070148390A1 (en) * 2005-12-27 2007-06-28 Specialty Coating Systems, Inc. Fluorinated coatings
US8404896B2 (en) * 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
EP2160386B1 (en) * 2007-05-23 2012-07-11 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
RU2520098C2 (ru) 2008-06-26 2014-06-20 Ресверлоджикс Корп. Способы получения производных хиназолинона
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
MX2011005096A (es) * 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
NZ617779A (en) 2009-03-18 2015-08-28 Resverlogix Corp Novel anti-inflammatory agents
KR20180096823A (ko) 2009-04-22 2018-08-29 리스버로직스 코퍼레이션 신규한 소염제
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
RS58911B1 (sr) 2011-11-01 2019-08-30 Resverlogix Corp Oralne formulacije sa trenutnim otpuštanjem za supstituisane hinazolinone
BR112014019476A8 (pt) * 2012-02-13 2017-07-11 Hoffmann La Roche Novos derivados de imidazolilcetona
PL2909192T3 (pl) * 2012-10-16 2017-09-29 Janssen Pharmaceutica Nv Połączone metylenem modulatory chinolinylowe ROR-GAMMA-T
ES2628365T3 (es) * 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
AU2013331493A1 (en) * 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
BR112016008258A2 (pt) 2013-10-15 2017-10-10 Janssen Pharmaceutica Nv moduladores de ror?t de quinolinila
AU2014334619A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORyt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
BR112016030273A8 (pt) 2014-06-24 2021-05-18 Icon Medical Corp dispositivo médico e método para formar o referido dispositivo
EP3233086B1 (en) * 2014-12-18 2023-02-15 University of South Carolina Suppression of neointimal formation following vascular surgery using cdk8 inhibitors
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
JP2018517673A (ja) 2015-04-21 2018-07-05 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ロナファルニブおよびリトナビルを含む医薬組成物
CN108371711A (zh) 2015-08-17 2018-08-07 库拉肿瘤学公司 使用法尼基转移酶抑制剂治疗癌症患者的方法
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN108883091A (zh) 2015-12-22 2018-11-23 X4 制药有限公司 用于治疗免疫缺陷病的方法
US11766506B2 (en) 2016-03-04 2023-09-26 Mirus Llc Stent device for spinal fusion
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
SG11201903786UA (en) 2016-11-03 2019-05-30 Kura Oncology Inc Farnesyltransferase inhibitors for use in methods of treating cancer
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN110204487B (zh) * 2019-06-21 2021-09-28 江南大学 一种喹啉衍生物的合成方法
CN113072490B (zh) * 2021-03-26 2022-08-16 中国海洋大学 一种替吡法尼喹啉酮中间体的高效合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE456347B (sv) 1982-02-09 1988-09-26 Ird Biomaterial Ab Ytmodifierat fast substrat samt forfarande for framstellning derav
US5049403A (en) 1989-10-12 1991-09-17 Horsk Hydro A.S. Process for the preparation of surface modified solid substrates
US5213898A (en) 1989-10-12 1993-05-25 Norsk Hydro A.S. Process for the preparation of surface modified solid substrates
US5356433A (en) 1991-08-13 1994-10-18 Cordis Corporation Biocompatible metal surfaces
JPH07112930A (ja) * 1993-10-14 1995-05-02 Kyowa Hakko Kogyo Co Ltd 血管平滑筋細胞増殖抑制剤
KR19990007865A (ko) 1995-04-19 1999-01-25 스피겔알렌제이 약물 방출용 피복 스텐트
US5607475A (en) 1995-08-22 1997-03-04 Medtronic, Inc. Biocompatible medical article and method
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
IL123568A (en) * 1995-12-08 2001-08-08 Janssen Pharmaceutica Nv History (Imidazole - 5Il) Methyl-2-quinolinone inhibitors of Prenzyl transferase, their preparation, pharmaceutical preparations containing them and their preparation and drugs containing them
TR199902923T2 (xx) 1997-06-02 2000-11-21 Janssen Pharmaceutica N.V. Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri.

Also Published As

Publication number Publication date
HK1088820A1 (en) 2006-11-17
WO1998055124A1 (en) 1998-12-10
CN1762355A (zh) 2006-04-26
AU8020798A (en) 1998-12-21
US20040198771A1 (en) 2004-10-07
CN1265585A (zh) 2000-09-06
EP0988038B1 (en) 2002-08-14
ID24675A (id) 2000-07-27
KR20010012782A (ko) 2001-02-26
CN100525766C (zh) 2009-08-12
IL133212A (en) 2005-12-18
CA2290992C (en) 2008-02-12
IL133212A0 (en) 2001-03-19
DK0988038T3 (da) 2002-12-02
CA2290992A1 (en) 1998-12-10
CN1231215C (zh) 2005-12-14
US6734194B2 (en) 2004-05-11
DE69807222D1 (de) 2002-09-19
PT988038E (pt) 2002-12-31
NO995883D0 (no) 1999-12-01
ES2182327T3 (es) 2003-03-01
US20020091138A1 (en) 2002-07-11
US20030229118A1 (en) 2003-12-11
NO995883L (no) 2000-02-02
NO318834B1 (no) 2005-05-09
US6743805B2 (en) 2004-06-01
ATE222104T1 (de) 2002-08-15
AU740603B2 (en) 2001-11-08
US6365600B1 (en) 2002-04-02
JP2002503235A (ja) 2002-01-29
DE69807222T2 (de) 2003-04-17
HK1025046A1 (en) 2000-11-03
BR9810423A (pt) 2000-10-03
EP0988038A1 (en) 2000-03-29
NZ501401A (en) 2002-03-28
KR100517832B1 (ko) 2005-09-30
US7253183B2 (en) 2007-08-07
RU2209066C2 (ru) 2003-07-27
ZA984700B (en) 1999-12-01
JP4209472B2 (ja) 2009-01-14

Similar Documents

Publication Publication Date Title
TR199902923T2 (xx) Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri.
TR199900781T2 (xx) H�cre yap��ma inhibit�rleri
NO971538L (no) Purin- og guaninforbindelser som inhibitorer for PNP
DE69618231T2 (de) TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER
HUP0004592A2 (hu) VCAM-1 expresszió gátlására alkalmas vegyületek és eljárások
MY120994A (en) 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives
BR9810459A (pt) sais nìtricos dos inibidores de ace
IL141410A0 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
EP1163208A4 (en) CASPASE INHIBITORS AND THEIR USE
DE69719778D1 (de) Benzonaphthyridine als bronchialtherapeutika
NO20052989D0 (no) Terapeutiske forbindelser.
EP1208092A4 (en) SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR
PT941221E (pt) Dihidrobenzofuranos substituidos como inibidores de fosfodiesterase (pde)
TR199900157T2 (xx) H�cre proliferasyon inhibisyonu i�in ikame edilmi� bisindolilmaleimidleri.
SV2002000244A (es) Metodos y compuestos para inhibir mrp1 ref.x-13353
PT920426E (pt) Novos derivados de tiazole com efeito inibidor de fosfodiesterase
MY121046A (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
DK1000034T3 (da) Substituerede 6-alkylphenanthridiner
DE69817810D1 (de) Cyanoguanidine als zellproliferation inhibitoren
TR200100133T2 (tr) FKBP İnhibitörleri
PT944618E (pt) Novos compostos de n-benzenossulfonilo-1-prolina processo de preparacao e utilizacao em terapia
ATE286892T1 (de) Hydroxam- und carbonsäurederivate mit mmp- und tnf-hemmender aktivität
SI0937075T1 (en) New Imidazo- and Oxazolopyridines as Phosphodiesterase Inhibitors.
SU1455608A1 (ru) 9,10-дизамещенные 9,10-дигидроантрацена в качестве ингибиторов коррозии стали в кислой среде
SU1540328A1 (ru) Ингибитор сероводородной коррозии стали